Pages that link to "Q43985739"

The following pages link to High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study (Q43985739):

Displaying 47 items.

• Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging (Q24650528) (← links)
• The Contribution of Advanced Glycation End product (AGE) accumulation to the decline in motor function (Q26767495) (← links)
• Serum carboxymethyl-lysine, disability, and frailty in older persons: the Cardiovascular Health Study (Q30578167) (← links)
• Association between hemoglobin glycation index with insulin resistance and carotid atherosclerosis in non-diabetic individuals. (Q33584606) (← links)
• Cardiac remodeling in obesity. (Q34043589) (← links)
• Poor 1-year outcomes after percutaneous coronary interventions in systemic lupus erythematosus: report from the National Heart, Lung, and Blood Institute Dynamic Registry (Q34156600) (← links)
• Insulin Resistance is an Independent Correlate of High Serum Levels of Advanced Glycation End Products (AGEs) and Low Testosterone in Non‐Diabetic Men (Q34185801) (← links)
• Advanced glycation/glycoxidation endproduct carboxymethyl-lysine and incidence of coronary heart disease and stroke in older adults (Q34217710) (← links)
• Influence of +1245 A/G MT1A polymorphism on advanced glycation end-products (AGEs) in elderly: effect of zinc supplementation (Q34232756) (← links)
• Atorvastatin inhibits the expression of RAGE induced by advanced glycation end products on aortas in healthy Sprague-Dawley rats (Q34269548) (← links)
• Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study (Q34507243) (← links)
• Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1 (Q35060239) (← links)
• Oxidized LDL and Fructosamine Associated with Severity of Coronary Artery Atherosclerosis in Insulin Resistant Pigs Fed a High Fat/High NaCl Diet (Q35684097) (← links)
• Advanced glycation end products (AGEs) in relation to atherosclerotic lipid profiles in middle-aged and elderly diabetic patients (Q35800420) (← links)
• Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography (Q36426832) (← links)
• Plasma Levels of Advanced Glycation End Products Are Related to the Clinical Presentation and Angiographic Severity of Symptomatic Lower Extremity Peripheral Arterial Disease (Q36593852) (← links)
• Hypothesis: the 'metabolic memory', the new challenge of diabetes (Q36816188) (← links)
• sRAGE and risk of diabetes, cardiovascular disease, and death (Q36867450) (← links)
• Pulse pressure and adverse outcomes in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) (Q36980709) (← links)
• Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events (Q37158807) (← links)
• Identifying advanced glycation end products as a major source of oxidants in aging: implications for the management and/or prevention of reduced renal function in elderly persons (Q37214116) (← links)
• Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. (Q37373486) (← links)
• Potential inhibitory effects of L-carnitine supplementation on tissue advanced glycation end products in patients with hemodialysis (Q37406686) (← links)
• Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. (Q37417494) (← links)
• A Comparative Study on Skin and Plasma Advanced Glycation End Products and Their Associations with Arterial Stiffness. (Q37622708) (← links)
• Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms (Q37636453) (← links)
• Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging (Q37641049) (← links)
• Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes. (Q37693552) (← links)
• The emerging challenge in diabetes: the "metabolic memory". (Q38011508) (← links)
• Proteomics of plaques and novel sources of potential biomarkers for atherosclerosis (Q38106664) (← links)
• Advanced Glycation End Products, Inflammation, and Chronic Metabolic Diseases: Links in a Chain? (Q38254631) (← links)
• Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects (Q39711731) (← links)
• Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients (Q39820086) (← links)
• Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. (Q40117639) (← links)
• Sleep-disordered breathing is associated with higher carboxymethyllysine level in elderly women but not elderly men in the cardiovascular health study (Q40395189) (← links)
• Hypothesis: the "metabolic memory", the new challenge of diabetes (Q43180132) (← links)
• Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study (Q44182907) (← links)
• Low-density lipoprotein levels are one of the independent determinants of circulating levels of advanced glycation end products in nondiabetic subjects. (Q45915232) (← links)
• Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes (Q47687003) (← links)
• Advanced glycation end products in myocardial reperfusion injury. (Q51373390) (← links)
• Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects (Q51553376) (← links)
• Circulating Concentrations of Redox Biomarkers Do Not Improve the Prediction of Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. (Q52686161) (← links)
• Associations of Serum Levels of Advanced Glycation end Products with Nutrition Markers and Anemia in Patients with Chronic Kidney Disease (Q57825178) (← links)
• Association of fried food consumption with all cause, cardiovascular, and cancer mortality: prospective cohort study (Q61810953) (← links)
• Exploring the role of body mass index in relationship of serum nitric oxide and advanced glycation end products in apparently healthy subjects (Q64109351) (← links)
• Glycation of macrophages induces expression of pro-inflammatory cytokines and reduces phagocytic efficiency (Q92451047) (← links)
• Implications of advanced oxidation protein products (AOPPs), advanced glycation end products (AGEs) and other biomarkers in the development of cardiovascular diseases (Q93107829) (← links)